INTRODUCTION
============

Biliary strictures can be challenging, both in terms of their diagnosis and in terms of their treatment (both curative and palliative) \[[@b1-ce-2019-053],[@b2-ce-2019-053]\]. Establishing a tissue diagnosis of malignancy before surgery is an important step when evaluating patients with a suspected malignant biliary stricture \[[@b3-ce-2019-053]\]. However, most patients presenting with obstructive symptoms are not candidates for surgery, either owing to locally invasive or metastatic cancer \[[@b4-ce-2019-053],[@b5-ce-2019-053]\]. Only 10% to 15% of pancreatic cancers and 20% to 49% of cholangiocarcinomas (CCAs) are resectable. For patients for whom palliative therapy is indicated, chemotherapy or radiotherapy requires a definitive histological diagnosis \[[@b6-ce-2019-053]-[@b8-ce-2019-053]\]. Currently, two methods are most widely available for the pathological diagnosis of a suspected malignant biliary stricture: endoscopic retrograde cholangiopancreatography (ERCP)-based tissue sampling and endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) \[[@b3-ce-2019-053],[@b9-ce-2019-053]\].

ERCP-based tissue sampling methods include biliary brush cytology (BC) and intraductal forceps biopsy (FB), with sensitivities ranging from 30% to 78% for BC \[[@b10-ce-2019-053]-[@b13-ce-2019-053]\] and from 29% to 81% for FB \[[@b10-ce-2019-053],[@b14-ce-2019-053]-[@b18-ce-2019-053]\], with higher yields usually found when both methods are combined \[[@b1-ce-2019-053],[@b2-ce-2019-053],[@b5-ce-2019-053]\]. As expected, ERCP-based tissue sampling produces better results for intraductal compared to extraductal lesions. A recent study showed an accuracy of 82.4% for intraductal lesions compared to 54.8% for extraductal lesions \[[@b2-ce-2019-053]\].

EUS-FNA allows for complete visualization of the pancreas and adjacent organs, and therefore targeted tissue acquision \[[@b19-ce-2019-053]-[@b21-ce-2019-053]\]. EUS-FNA is considered by most to be the gold-standard technique for pancreatic masses, which are the most common cause of malignant biliary strictures \[[@b22-ce-2019-053],[@b23-ce-2019-053]\]. Additionally, a recent systematic review and meta-analysis demonstrated that the pooled sensitivity and specificity of EUS-FNA for malignant biliary obstructions were 75% and 100%, respectively \[[@b24-ce-2019-053]\]. This satisfactory yield is achievable in the absence of an identifiable mass on previous imaging \[[@b25-ce-2019-053]\] and in the setting of suspected CCA with sensitivity ranging from 73% to 89% \[[@b26-ce-2019-053]-[@b29-ce-2019-053]\].

Even though EUS-FNA and ERCP-based tissue sampling have been compared extensively in the diagnosis of biliary strictures, few studies have evaluated the combination of these methods in same-session procedures in comparison to either modality alone. Therefore, the aim of this analysis was to evaluate the performance of EUS-FNA and ERCP-based tissue sampling in same-session procedures, and to identify an optimal tissue acquisition strategy for suspected malignant biliary strictures.

MATERIALS AND METHODS
=====================

Protocol and registration
-------------------------

This systematic review and meta-analysis was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations \[[@b30-ce-2019-053]\]. The review was registered in PROSPERO international database (CRD42019119042) and can be accessed at <http://www.crd.york.ac.uk/PROSPERO>.

Eligibility criteria
--------------------

Clinical trials and observational studies were evaluated; case reports and abstracts were not eligible. Patients with a suspected malignant biliary stricture (without cytohistological diagnosis) who underwent same-session EUS-FNA and ERCP-based tissue sampling were included. Additionally, a "gold-standard" comparison procedure (i.e., surgical histology or tissue sampling) with a six-month follow-up period was required for inclusion. The main outcome was the accuracy of ERCP-based tissue sampling and EUS-FNA in the diagnosis of suspected malignant biliary strictures. Secondary outcomes included the accuracy of each diagnostic method in specific pancreatic and biliary etiologies. Also, a comparison between FB and BC was performed. Outcome measures included sensitivity, specificity, positive likelihood ratio (+LR), negative likelihood ratio (--LR), and area under the curve (AUC).

### Search

The following search strategy was used in the Medline database: (cholangiocarcinoma OR bile duct neoplasms OR biliary stricture OR pancreatic cancer OR pancreatic mass OR ampullary cancer OR biliary stenosis OR chronic pancreatitis OR adenocarcinoma OR gallbladder cancer OR bile duct cancer OR biliary tumor OR Klatskin tumor) AND (EUS OR endoscopic ultrasonography OR echoendoscopy OR FNA OR fine needle aspiration OR FNB OR fine needle biopsy) AND (ERCP OR endoscopic retrograde cholangiopancreatography OR biopsy OR brush OR cytology). In the EMBASE, Cochrane, LILACS, Scopus, and CINAHL databases, the search was summarized into "biliary stricture and ERCP and endoscopic ultrasound." The last search was performed on 02/January/2019.

### Study selection

The articles were selected after an initial assessment of the titles and abstracts in order to assess the relevancy of the full text. The selection was performed by three independent reviewers. Disagreements between the reviewers were resolved via a discussion with all authors. To summarize the study selection processes, an adapted PRISMA flow diagram was used ([Fig. 1](#f1-ce-2019-053){ref-type="fig"}) \[[@b31-ce-2019-053]\].

### Data collection process

The data were collected from the absolute values provided or inferred based on information reported in the included studies. A Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-based checklist was used and the collected data were placed into 2×2 tables \[[@b32-ce-2019-053],[@b33-ce-2019-053]\]. These tables separated the true positives (TP), false positives (FP), true negatives (TN), and false negatives (FN). Only studies that provided all the information necessary to complete the table for at least one analysis were included in the meta-analysis. This process was performed by three independent reviewers and revised by all authors. Disagreements were resolved by consensus among the authors.

### Data items

Population characteristics (number of patients with suspected malignant biliary strictures included in the analysis, clinical indications for the procedure), study design, gold-standard method used, EUS-FNA, and ERCP-based tissue sampling results were obtained from the included studies. The term "same-session tissue sampling" was defined as EUS and ERCP sampling procedures performed on the same day or within a maximum of 14 days without knowledge of prior cytopathologic results. Patients with malignant lesions on both endoscopic sampling and gold standard methods were considered TP, whereas patients with benign lesions on both endoscopic sampling and gold-standard methods were considered TN. Patients who had malignant disease (based on the gold standard evaluation) that was classified as benign by endoscopic methods were considered FN, whereas patients who had benign lesions (based on the gold standard evaluation) that was classified as malignant by endoscopic procedures were considered FP.

### Risk of bias

To evaluate the risk of bias and applicability of primary diagnostic accuracy, the QUADAS-2 tool was used. This tool consists of four key domains, each of which are assessed in terms of risk of bias: patient selection, index test, reference standard, and flow and timing. The first three domains are also assessed in terms of applicability.

### Summary measures and synthesis of results

For the quantitative analysis, sensitivity, specificity, +LR and --LR values are presented in Forest plots. Additionally, summary receiver operating characteristic (sROC) curves and estimations of the AUCs were performed. All variables were subjected to intention-to-treat (ITT) analysis, where atypical and suspicious cases were considered malignant, and acquisition failure and inconclusive cases were considered benign. I-square was used to evaluate heterogeneity. Due to the heterogeneity among the studies, the Dersimonian Laird random effects model was used in the analysis. The sROC curves were created using the Moses-Littenberg linear model. Data entered (including TP, FP, TN, and FN) were converted to percentage values and graphs by the software Meta-DiSc version 1.4. Additionally, the adverse events for each study were reported.

RESULTS
=======

Study selection
---------------

In the initial search, 12,132 studies were screened and assessed for eligibility based on their titles and abstracts. Of these, 12,062 were excluded because they were not related to our objective. Of the remaining 70 studies, 64 did not meet inclusion criteria and were excluded. Therefore, a total of six studies \[[@b2-ce-2019-053],[@b3-ce-2019-053],[@b5-ce-2019-053],[@b6-ce-2019-053],[@b9-ce-2019-053],[@b34-ce-2019-053]\] were included for qualitative analysis, including four \[[@b2-ce-2019-053],[@b3-ce-2019-053],[@b5-ce-2019-053],[@b34-ce-2019-053]\] prospective and two \[[@b6-ce-2019-053],[@b9-ce-2019-053]\] retrospective studies. These studies also provided adequate information for inclusion in the quantitative analysis. This process is summarized in [Fig. 1](#f1-ce-2019-053){ref-type="fig"}.

Study characteristics
---------------------

The important characteristics of the selected studies are summarized in [Table 1](#t1-ce-2019-053){ref-type="table"}. These data were extracted through careful reading of included papers. The design, patient characteristics, lesion characteristics, interventions, and gold standard methods of diagnosis were similar for among these studies. The inclusion criteria were jaundice or elevated liver functions tests and suspected malignant biliary stricture identified on imaging. The main objective of all included studies was to evaluate same-session EUS/ERCP-based tissue sampling in the diagnosis of malignant biliary strictures.

Risk of bias within and across studies
--------------------------------------

Using QUADAS-2, we found that the risk of bias within studies was low. When assessing risk of bias during patient selection, we found that all studies demonstrated a low risk of bias. Regarding interpretation of the index test and gold-standard methods, all studies also showed a low risk of bias. Additionally, patient flow did not introduce bias in any included study ([Table 2](#t2-ce-2019-053){ref-type="table"}).

Results of individual studies
-----------------------------

Pretest probability, sensitivity, specificity, positive predictive value, negative predictive values, and accuracy were assessed in all studies. The prevalence of malignant disease was \>50% in all included studies. During our evaluation, we found that the specificity of both tests was satisfactory in all studies with values ranging from 88.9% to 100%. EUS-FNA was more accurate than ERCP-based tissue sampling in all studies except for the study by Rösch et al., in which both methods demonstrated similar results \[[@b5-ce-2019-053]\].

Synthesis of results
--------------------

A total of six studies were included in the ITT analysis, for a total of 497 patients. Of these, 432 (86.92%) patients had lesions that were considered malignant (268 pancreatic masses, 90 CCAs, 15 cases of gallbladder cancer, 4 neuroendocrine tumors, 3 metastases, and 52 other lesions) and 65 (13.08%) patients had lesions that were considered benign (22 cases of chronic pancreatitis, 13 cases of autoimmune pancreatitis, and 30 other lesions). The number of studies included in each analysis varied according to the available data in each study.

First, the association between EUS-FNA and ERCP-based tissue sampling was analyzed. This analysis included 5 studies, and the results were: pooled sensitivity of 86% (0.83--0.90), I^2^=78.5%; pooled specificity of 98% (0.91--1.00), I^2^=0%; pooled +LR of 12.50 (4.23--36.88) I^2^=0%; and pooled --LR of 0.17 (0.11--0.28), I^2^=54% ([Fig. 2](#f2-ce-2019-053){ref-type="fig"}). Additionally, the AUC was 0.9656 ([Fig. 3](#f3-ce-2019-053){ref-type="fig"}).

When comparing EUS-FNA to ERCP-based tissue sampling, all six studies were included in the analysis. EUS-FNA showed better results than ERCP. For EUS-FNA, the pooled sensitivity, specificity, +LR, --LR and AUC were: 76% (0.72--0.80), I^2^=87.3%; 100% (0.94--1.00), I^2^=0%; 10.95 (3.73--32.13), I^2^=0%; 0.27 (0.18--0.43), I^2^=78.2%; and 0.9458, respectively ([Fig. 4](#f4-ce-2019-053){ref-type="fig"}). For ERCP, the pooled sensitivity, specificity, +LR, --LR and AUC were: 58% (0.53--0.62), I^2^=65.9; 98% (0.92--1.00), I^2^=0%; 7.51 (2.75--20.51), I^2^=0%; 0.47 (0.40--0.56), I^2^=21.9%; and 0.7819, respectively ([Fig. 5](#f5-ce-2019-053){ref-type="fig"}).

Secondly, a comparison between methods was performed for pancreatic and biliary etiologies individually. In this analysis four studies were included. In the pancreatic lesions analysis, Moura et al. \[[@b2-ce-2019-053]\] was excluded since this study did not report any benign cases of pancreatic lesions, preventing the calculations of specificity and +LR. In the pancreatic analysis, EUS-FNA was superior to ERCP-based tissue sampling. For EUS-FNA, the pooled sensitivity, specificity, +LR, --LR and AUC were: 75% (0.69--0.81), I^2^=80.7%; 100% (0.87--100), I^2^=0%; 10.59 (2.29--48.91), I^2^=0%; 0.27 (0.16--0.47), I^2^=56.5%; and 0.9422, respectively ([Fig. 6](#f6-ce-2019-053){ref-type="fig"}). For ERCP-based tissue sampling, the pooled sensitivity, specificity, +LR, --LR and AUC were: 47% (0.40--0.53), I^2^=78.1%; 100% (0.87--1.00), I^2^=0%; 4.90 (1.02--23.59), I^2^=0%; 0.66 (0.43--1.01), I^2^=82.3%; and 0.7930; respectively ([Fig. 7](#f7-ce-2019-053){ref-type="fig"}). In the biliary lesion analysis, both methods had similar results. For EUS-FNA, the sensitivity, specificity, +LR, --LR, and accuracy were: 71% (0.62--0.79), I^2^=76.4%; 100% (0.86--1.00), I^2^=0%; 10.35 (1.56--21.28), I^2^=0%; 0.38 (0.19--0.75), I^2^=79.6%; and 0.8832 ([Fig. 8](#f8-ce-2019-053){ref-type="fig"}). For ERCP-based tissue sampling, the sensitivity, specificity, +LR, --LR, and accuracy were: 74% (0.65--0.82), I^2^=0%; 100% (0.86--1.00), I^2^=0%; 7.03 (1.93--25.65), I^2^=0%; 0.29 (0.21--0.41); 0.8097 ([Fig. 9](#f9-ce-2019-053){ref-type="fig"}). [Table 3](#t3-ce-2019-053){ref-type="table"} summarizes all the meta-analysis results from EUS-FNA and ERCP-based tissue sampling.

Third, both ERCP-based tissue sampling methods (i.e., BC and FB) were compared individually. In the individual analysis, each method produced inferior results compared to both methods combined. For BC, four studies \[[@b2-ce-2019-053],[@b5-ce-2019-053],[@b6-ce-2019-053],[@b34-ce-2019-053]\] were analyzed; for FB, two studies \[[@b2-ce-2019-053],[@b5-ce-2019-053]\] were analyzed. The BC analysis showed a sensitivity and specificity of 54% (0.46--0.63), I^2^=0%; and 97% (0.86--1.00), I^2^=0%, respectively. The FB analysis showed a sensitivity and specificity of 43% (0.32--0.55), I^2^=7.5%; and 100% (0.86--1.00), I^2^=0%, respectively.

The adverse events related to the combination of the procedures in each study are described in [Table 4](#t4-ce-2019-053){ref-type="table"}.

DISCUSSION
==========

Biliary strictures can emerge from the epithelium, such as in primary sclerosing cholangitis or CCA, or due to extraluminal compression from masses or regional inflammatory processes.

When a mass is clearly defined, diagnosis is often easily obtained via EUS-FNA, with a sensitivity and accuracy of up to 95%. Conversely, a stricture after liver transplantation or following iatrogenic bile duct injury, can easily be diagnosed as benign. However, when a clear mass is absent, and the clinical history is poor or unclear, differentiation between benign and malignant biliary strictures can be challenging. In such cases, confirmation through histological diagnosis is crucial to, firstly, avoid operations of a benign disease with potentially undue morbidity and mortality, or secondly, leave an undiagnosed malignancy unchecked \[[@b1-ce-2019-053],[@b2-ce-2019-053],[@b35-ce-2019-053],[@b36-ce-2019-053]\].

Seeking to define the best approach for tissue diagnosis of biliary strictures, we conducted this systematic review and meta-analysis to report performance data on same-session EUS-FNA and ERCP-based tissue sampling. We included all studies \[[@b2-ce-2019-053],[@b3-ce-2019-053],[@b5-ce-2019-053],[@b6-ce-2019-053],[@b9-ce-2019-053],[@b34-ce-2019-053]\] that performed ERCP-based tissue sampling and EUS-FNA in the diagnosis of malignant biliary strictures in the same-session or within a few days in some cases. In four studies \[[@b2-ce-2019-053],[@b3-ce-2019-053],[@b5-ce-2019-053],[@b9-ce-2019-053]\], during ERCP, both BC and FB were performed, and in two studies \[[@b6-ce-2019-053],[@b34-ce-2019-053]\], just BC was performed.

Most histopathology reports use five different categories including inadequate, benign, atypical, suspect or malignant \[[@b2-ce-2019-053],[@b37-ce-2019-053]\]. Diagnostic studies disagree on whether to consider cases with suspicious results as malignant or benign, and this fact is related to the heterogeneity of diagnostic yields reported in the literature. To avoid heterogeneity in our findings, in our analysis, we included data in an ITT analysis and considered atypical and cases with suspicious results as malignant, and inconclusive cases as benign.

Our first goal was to analyze the diagnostic yield of same-session EUS-FNA and ERCP-based tissue sampling. The pooled sensitivity was higher when the methods were combined compared to either method alone. With both methods combined we found a pooled sensitivity of 86%, with a +LR of 12.50, meaning that a malignant result can be trusted. However, even with both methods combined, the --LR was 0.17, meaning a negative result for a suspected malignant lesion. Therefore, these results should be interpreted with caution, and cannot exclude malignancy. Theoretically, the combined use of these techniques could increase the number of complications, since the patients would be exposed to more than one procedure. In our systematic review, we cited---but did not specifically study---adverse events. However, all included studies show similar adverse event rates in comparison to single method studies.

Second, we compared EUS-FNA versus ERCP-based tissue sampling and found that EUS-FNA had significantly higher overall accuracy in the diagnosis of malignant biliary strictures, with a sensitivity of 76% versus 58%. EUS-FNA is considered the gold standard for pancreatic lesions \[[@b22-ce-2019-053],[@b38-ce-2019-053],[@b39-ce-2019-053]\], and the majority of the included participants had pancreatic lesions. Considering the fact that extraductal lesions cannot be adequately sampled during an ERCP-based tissue sampling from a neighboring stricture unless they invade its lumen \[[@b40-ce-2019-053]\], we also performed a subgroup analysis on just pancreatic lesions. For pancreatic lesions causing biliary strictures, EUS-FNA showed higher diagnostic accuracy compared to ERCP-based tissue sampling, with a sensitivity of 75% versus 47%, respectively. Additionally, since ERCP-based tissue sampling produces better results for primary biliary lesions (which originate from the biliary epithelium) compared to extraductal lesions, we performed a subgroup analysis on just biliary lesions, and found similar results between both methods, with sensitivity of 71% for EUS-FNA versus 74% for ERCP-based tissue sampling.

In our third analysis, we performed a meta-analysis on the results of BC and FB during ERCP-based tissue sampling for the included studies. We found that BC was slightly superior to FB, with a sensitivity of 54% versus 43%. Comparing the individual results of each method to the combination of both, we found that combining methods resulted in a sensitivity of 58%, which is higher than either FB or BC alone.

Our systematic review and meta-analysis has some limitations. First, there are no randomized controlled trials available in the literature. Additionally, due to the small number of prospective studies that compare same-session procedures, we included two retrospective studies in our analysis. Second, the fact that the majority of included patients have pancreatic lesions may be considered a limitation as this may bias the results towards EUS-FNA. However, to minimize this bias, we performed individual analyses of pancreatic and biliary lesions. Third, from the six included studies, two studies \[[@b3-ce-2019-053],[@b34-ce-2019-053]\] used rapid on-site evaluation. This may have impacted our results because rapid on-site evaluation was just performed in the EUS-FNA procedures and not in the ERCP-based tissue sampling procedures, potentially favoring the EUS-FNA group. A meta-analysis showed that rapid on-site evaluation is associated with up to 3.5% improvement in adequacy rates for EUS-FNA \[[@b41-ce-2019-053]\]. Fourth, and probably the most important limitation of this study, is that the included studies do not report enough data for a meta-analysis separating lesion by size (for example, larger or smaller than 2 cm). This is notable, as larger lesions can favor EUS-FNA. Fifth, this analysis did not include EUS-fine needle biopsy data which is now more commonly performed with favorable results compared to EUS-FNA \[[@b42-ce-2019-053]\]. Finally, this analysis also does not include advanced cytopathologic analysis such as fluorescence in situ hybridization, which could improve the diagnostic yield \[[@b43-ce-2019-053]\].

It's worth noting that EUS-FNA provided better results for masses compared to focal wall thickness or small infiltrative tumors. For these intraductal biliary tumors, there is a place for cholangioscopy, which allows for a biopsy with directed visualization, and can solve the significant problem of indeterminate biliary stricture \[[@b44-ce-2019-053]\]. In our systematic review, we do not include any study that performed cholangioscopy. Additionally, the use of EUS-FNA in first-line diagnosis of CCA is considered somewhat controversial given the theoretical implications for peritoneal spread and subsequent liver transplantation candidacy \[[@b45-ce-2019-053]\], although this idea is not universally shared \[[@b46-ce-2019-053],[@b47-ce-2019-053]\].

In summary, our systematic review and meta-analysis revealed that both methods have high specificities and high positive predictive values in diagnosing suspected biliary strictures. However, both have low negative predictive values and therefore, a negative result cannot exclude malignancy. Our results show that a combination of the two methods is the best approach for the tissue diagnosis of a malignant biliary stricture. Nevertheless, the decision to perform concomitant EUS/ERCP is not universal given subtle differences in clinical scenarios. However, single-session EUS/ERCP should be considered whenever possible to maximize diagnostic yield.

CONCLUSIONS
===========

Same-session EUS-FNA and ERCP-based tissue sampling is superior to either method alone in the diagnosis of suspected malignant biliary strictures. In the individual general analysis, as well as for pancreatic lesions, EUS-FNA is superior to ERCP-based tissue sampling. However, for biliary etiologies these methods have similar accuracy. Considering these results, combination sampling should be performed when possible.
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###### 

Characteristics of Included Studies

  Study                                                           Patients (*n*)                                                                            Age (yr)                                                                                                                                                                                   Lesion size                                              Intervention                                                       Gold standard                                                                                                                                          Final diagnosis
  --------------------------------------------------------------- ----------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------- ------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------ -----------------
  Jo et al. (2019) \[[@b9-ce-2019-053]\]                          263                                                                                       64.6±10.5                                                                                                                                                                                  26.9±11.6 mm                                             EUS-FNA (22 G, 25H, 20 G and 19 G): 2.7 (±1.2) passes              1\) Surgical pathology;                                                                                                                                Malignant: 239
  M: 167                                                          2\) pathologic diagno- sis made by any tissue acquisition method; 3) follow-up (\>6 mo)   \- Pancreatic mass: 163                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  　Design: Retrospective                                         F: 96                                                                                     ERCP: 3 (1--7) intraductal biopsy in 246/257 cases and cytology (via endoscopic nasobiliary drainage or brushing in all cases)                                                             \- CCA: 53                                                                                                                                                                                                                                                                         
  \- Gallbladder cancer: 14                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  \- Other: 9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Benign: 24                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  \- Autoimmune pancreatitis: 12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  \- Chronic pancreatitis: 5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  \- Other: 7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Moura et al. (2018) \[[@b2-ce-2019-053]\]                       50                                                                                        63.08 (41--86)                                                                                                                                                                             3.48±1.72 cm                                             EUS-FNA (22 G): 4 passes                                           1\) Surgical pathology;                                                                                                                                Malignant: 48
  M: 24                                                           2\) clinical follow-up (\>6 mo)                                                           \- Adenocarcinoma: 36                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  　Design: Prospective                                           F: 26                                                                                     ERCP: 3 intraductal biopsies and 2 brush cytology                                                                                                                                          \- IPMN: 4                                                                                                                                                                                                                                                                         
  \- Metastases: 3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  \- Neuroendocrine tumor: 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  \- Adenosquamous: 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Weilert et al. (2014) \[[@b3-ce-2019-053]\]                     51                                                                                        67 (42--88)                                                                                                                                                                                N/A                                                      EUS-FNA (22 G or 25 G)---with ROSE                                 1\) Surgical findings/pathology; 2) EUS or ERCP sampling with definite evidence for malignancy; and 3) clinical follow-up (\>6 mo)                     Malignant: 48
  \- Pancreatic cancer: 34                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  　Design: Prospective                                           ERCP: 2 to 3 intraductal biopsies and brush cytology                                      \- CCA: 13                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  \- Gallbladder cancer: 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Benign: 3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  \- Autoimmune pancreatitis: 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  \- Chronic pancreatitis: 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  \- Autoimmune cholangiopathy: 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Novis et al. (2010) \[[@b34-ce-2019-053]\]                      46                                                                                        56 (40--87)                                                                                                                                                                                N/A                                                      EUS-FNA (22 G): at least 3 passes-with ROSE (by the endoscopist)   1\) Surgical pathology; 2) EUS or ERCP sampling with evidence for malignancy; and 3) clinical follow-up (\>6 mo for malignance and 24 mo for benign)   Malignant: 37
  M: 21                                                           \- Pancreatic cancer: 26                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  　Design: Prospective                                           F: 25                                                                                     ERCP brush cytology                                                                                                                                                                        \- Biliary: 11                                                                                                                                                                                                                                                                     
  \- Common bile duct: 8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  \- Hilar tumors: 3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Benign: 9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  \- Chronic pancreatitis: 8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  \- Fibrosis: 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Oppong et al. (2010) \[[@b6-ce-2019-053]\]                      37                                                                                        62.4 (26--87)                                                                                                                                                                              N/A                                                      EUS-FNA (22 G and 25 G): 2.7 (1--6) passes                         1\) Surgical histology or other biopsy methods;                                                                                                        Malignant: 32
  \- Pancreatic tumor: 29                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  　Design: Retrospective                                         ERCP brush cytology: at least 3 brushings                                                 2\) any positive cytology result combined with clinical follow-up with evidence of malignancy; 3) follow-up until death or for at least two years if there was no evidence of malignancy   \- Neuroendocrine tumor: 2                                                                                                                                                                                                                                                         
  \- CCA: 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Benign: 5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  \- Chronic pancreatitis: 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  \- Primary sclerosing cholangitis: 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  \- Serous cyst adenoma: 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  \- GIST: 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Rösch et al. (2004) \[[@b5-ce-2019-053]\]                       50                                                                                        N/A                                                                                                                                                                                        N/A                                                      EUS-FNA (22 G): at least 2 passes                                  1\) Surgery pathology                                                                                                                                  Malignant: 28
  M: 29                                                           ERCP: 6 intraductal biopsies and brush cytology (2 types of brush, 2 passes with each)    2\) Biopsy specimens obtained by other methods                                                                                                                                             \- Pancreatic tumors: 16                                                                                                                                                                                                                                                           
  　Design: Prospective                                           F: 21                                                                                     3\) A positive result for any tissue acquisition method being evaluated, plus clinical follow-up that provided further evidence of malignancy                                              \- Biliary tumors: 12 (8 common bile duct and 4 hilar)                                                                                                                                                                                                                             
  4\) Further evidence of malignancy (e.g., distant metastases)   Benign: 22                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  \- Chronic pancreatitis 6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  5\) 6-mo follow-up                                              \- CBD stricture: 16 (9 common bile duct and 7 hilar)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

CBD, common biliary duct; CCA, cholangiocarcinoma; ERCP, endoscopic retrograde cholangiopancreatography; EUS-FNA, endoscopic ultrasound-guided fine needle aspiration; GIST, gastrointestinal; IPMN, intraductal papillary mucinous neoplasms; N/A, not available; ROSE, rapid on site evaluation.

###### 

Quality Assessment of Diagnostic Accuracy Studies-2. Risk of Bias Across the Included Studies

  Study                                         Risk of bias             Applicability concerns                                                                                                       
  --------------------------------------------- ------------------------ ------------------------ ------------------------ ------------------------ ------------------------ ------------------------ ------------------------
  Jo et al. (2019) \[[@b9-ce-2019-053]\]        ![](ce-2019-053i1.jpg)   ![](ce-2019-053i1.jpg)   ![](ce-2019-053i1.jpg)   ![](ce-2019-053i1.jpg)   ![](ce-2019-053i1.jpg)   ![](ce-2019-053i1.jpg)   ![](ce-2019-053i1.jpg)
  Moura et al. (2018) \[[@b2-ce-2019-053]\]     ![](ce-2019-053i1.jpg)   ![](ce-2019-053i1.jpg)   ![](ce-2019-053i1.jpg)   ![](ce-2019-053i1.jpg)   ![](ce-2019-053i1.jpg)   ![](ce-2019-053i1.jpg)   ![](ce-2019-053i1.jpg)
  Weilert et al. (2014) \[[@b3-ce-2019-053]\]   ![](ce-2019-053i1.jpg)   ![](ce-2019-053i1.jpg)   ![](ce-2019-053i1.jpg)   ![](ce-2019-053i1.jpg)   ![](ce-2019-053i1.jpg)   ![](ce-2019-053i1.jpg)   ![](ce-2019-053i1.jpg)
  Novis et al. (2010) \[[@b34-ce-2019-053]\]    ![](ce-2019-053i1.jpg)   ![](ce-2019-053i1.jpg)   ![](ce-2019-053i1.jpg)   ![](ce-2019-053i1.jpg)   ![](ce-2019-053i1.jpg)   ![](ce-2019-053i1.jpg)   ![](ce-2019-053i1.jpg)
  Oppong et al. (2010) \[[@b6-ce-2019-053]\]    ![](ce-2019-053i1.jpg)   ![](ce-2019-053i1.jpg)   ![](ce-2019-053i1.jpg)   ![](ce-2019-053i1.jpg)   ![](ce-2019-053i1.jpg)   ![](ce-2019-053i1.jpg)   ![](ce-2019-053i1.jpg)
  Rösch et al. (2004) \[[@b5-ce-2019-053]\]     ![](ce-2019-053i1.jpg)   ![](ce-2019-053i1.jpg)   ![](ce-2019-053i1.jpg)   ![](ce-2019-053i1.jpg)   ![](ce-2019-053i1.jpg)   ![](ce-2019-053i1.jpg)   ![](ce-2019-053i1.jpg)
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###### 

Summary of the Meta-Analysis Results

  Method(s)                       Sensitivity (%)   Specificity (%)   Positive likelihood ratio   Negative likelihood ratio   Area under the curve- sROC
  ------------------------------- ----------------- ----------------- --------------------------- --------------------------- ----------------------------
  EUS + ERCP                      86 (81--90)       98 (91--100)      12.50 (4.23--36.88)         0.17 (0.11--0.28)           0.9656
  EUS                             76 (72--80)       100 (94--100)     10.95 (3.73--32.13)         0.27 (0.18--0.43)           0.9458
  ERCP                            58 (53--62)       98 (92--100)      7.51 (2.75--20.51)          0.47 (0.40--0.56)           0.7819
  EUS-FNA in pancreatic lesions   75 (65--81)       100 (87--100)     10.59 (2.29--48.91)         0.27 (0.16--0.47)           0.9422
  ERCP in pancreatic lesions      47 (40--53)       100 (87--100)     4.90 (1.02--23.59)          0.66 (0.43--1.01)           0.7930
  EUS-FNA in biliary lesions      71 (62--79)       100 (86--100)     5.77 (1.56--21.28)          0.38 (0.19--0.75)           0.8832
  ERCP in biliary lesions         74 (65--82)       100 (86--100)     7.03 (1.93--25.65)          0.29 (0.21--0.41)           0.8097

ERCP, endoscopic retrograde cholangiopancreatography; EUS-FNA, endoscopic ultrasound-guided fine needle aspiration; sROC, summary receiver operating characteristic.

###### 

Adverse Events Related to Combined Procedures of Each Included Study

  Study                                                                                        Patients, *n*   Adverse events, *n*(%)   Adverse events
  -------------------------------------------------------------------------------------------- --------------- ------------------------ -----------------------------------------
  Jo et al. (2019) \[[@b9-ce-2019-053]\]                                                       263             24 (9.12)                \- 8 bleedings
  \- 2 cholangitis                                                                                                                      
  \- 14 pancreatitis                                                                                                                    
  Moura et al. (2018) \[[@b2-ce-2019-053]\]                                                    50              3 (6)                    \- 2 mild pancreatitis
  \- 1 post sphincterotomy bleeding without hemodynamic repercussion, treated endoscopically                                            
  Weilert et al. (2014) \[[@b3-ce-2019-053]\]                                                  51              0                        No adverse events
  Novis et al. (2010) \[[@b34-ce-2019-053]\]                                                   46              5 (10.86)                \- 2 cholangitis treated endoscopically
  \- 1 mild pancreatitis                                                                                                                
  \- 1 biliary peritonitis. Surgical intervention was required. Patient died after surgery                                              
  \- 1 mild bleeding. No intervention was required                                                                                      
  Oppong et al. (2010) \[[@b6-ce-2019-053]\]                                                   37              2 (9.1)                  \- 1 mild pancreatitis
  \- 1 inadequate biliary drainage after procedures. Stent exchange was required                                                        
  Rösch et al. (2004) \[[@b5-ce-2019-053]\]                                                    50              0                        No adverse events
